| 重症肌无力的免疫耐受治疗 |
| |
| 引用本文： | 罗六一,任明山. 重症肌无力的免疫耐受治疗[J]. 国际免疫学杂志, 2009, 32(1): 54-57. DOI: 10.3760/cma.j.issn.1673-4394.2009.01.015 |
| |
| 作者姓名： | 罗六一 任明山 |
| |
| 作者单位： | 安徽医科大学附属省立医院,合肥,230001;安徽医科大学附属省立医院,合肥,230001 |
| |
| 基金项目： | 安徽省教育厅自然科学基金重点资助项目,安徽省人才开发基金重点资助项目 |
| |
| 摘 要： | 重症肌无力（MG）是累及神经一肌肉接头突触后膜上乙酰胆碱受体（AChR）的自身免疫性疾病,其发病的关键在于自我耐受的破坏,导致自身AChR出现异常的细胞免疫应答和体液免疫应答。这种抗AChR抗体的产生是T细胞依赖性的,故AChR特异性的T细胞就是MG特异性治疗的潜在靶位。随着免疫学的发展,MG免疫耐受治疗有可能会特异性地和有效地防止或阻断MG的发生与进展。
|
| 关 键 词： | 重症肌无力 乙酰胆碱受体 免疫耐受 |
The immune tolerance therapy for myasthenia gravis |
| |
| LUO Liu-yi,REN Ming-shan. The immune tolerance therapy for myasthenia gravis[J]. International Journal of Immunology, 2009, 32(1): 54-57. DOI: 10.3760/cma.j.issn.1673-4394.2009.01.015 |
| |
| Authors: | LUO Liu-yi REN Ming-shan |
| |
| Affiliation: | (Department of Neurology,Affiliated Provincial Hospital ,Anhui Medical University,Hefei 230001, China) |
| |
| Abstract: | Myasthenia gravis (MG) is an autoimmune disease associated with antibodies directed to the postsynaptic nicotinic acetylcholine receptor(AChR).Its essential pathogenesis is the failure of self tolerance,which results in abnormal cellular and humoral immune response to self AChR.The production of the AChR antibodies (AChR-Abs) is T cell dependent.Therefore the specific T cell is the potential target for MG specific therapy.As the progress of immunology,immune tolerance therapy for MG might specifically and effectively prevent or block the occurrence and development of MG. |
| |
| Keywords: | Myasthenia gravis Acetyleholine receptor Immune tolerance |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
